Company news
Prime Drink Group Corp (CSE:PRME) news
Prime Drink Group Corp news releases on 6ix. Latest, Oct 5, 2026: Canadian Investment Regulatory Organization Trade Resumption - PRME
Press releases & updates
Canadian Investment Regulatory Organization Trade Resumption - PRME
October 5, 2026
Prime Drink Group Announces Filing of Annual and Interim Financial Statements and Anticipated CTO Revocation
September 30, 2026
Canadian Investment Regulatory Organization Trading Halt - PRME
September 30, 2026
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
September 24, 2026
Prime Drink Group Finalizes Settlement With Creditors
September 21, 2026
Prime Drink Group Announces First Closing of Private Placement
September 10, 2026
Prime Drink Group Enters Into Strategic Partnership With Groupe Geloso to Accelerate the Expansion of Beach Day Every Day Across the Rest of Canada, the United States and Europe
August 27, 2026
Prime Drink Group Announces Execution of a Binding Letter of Intent for the Acquisition of Beach Day Every Day and Concurrent Financing
August 26, 2026
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 6, 2026
Prime Drink Group Extends Private Placement and Announces Delay in Filing Annual Financial Statements
July 30, 2026
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
July 23, 2026
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
July 8, 2026
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
June 22, 2026
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
June 18, 2026
Prime Drink Group Announces Private Placement and Agreed Resolution with Creditors
June 12, 2026
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
June 3, 2026
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
May 7, 2026
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
April 16, 2026
Prime Drink Group Announces Convertible Debenture, Board Appointment and Grant of Differed Share Units
April 13, 2026
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step
March 30, 2026
Advanced Cell-based Therapy Booming the Success for Healthcare Sector
March 24, 2026
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
March 3, 2026
Prime Drink Group Announces Management Change
February 27, 2026
Prime Drink Group Secures Exclusive North American Licenses for Beach Day Every Day
February 6, 2026
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference
January 7, 2026
Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize
January 2, 2026
Prime Drink Group Announces First Closing of Private Placement and Grant of Stock Options
December 30, 2025
Prime Drink Group Announces Private Placement
December 17, 2025
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
December 7, 2025
Prime Medicine to Present at 8th Annual Evercore Healthcare Conference
November 25, 2025
Prime Medicine to Present at Jefferies Global Healthcare Conference
November 11, 2025
CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 7, 2025
Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 7, 2025
Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer
November 3, 2025
Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy
October 30, 2025
Prime Medicine to Participate in Upcoming Investor Conferences
October 7, 2025
Prime Drink Group Provides Bi-Weekly MCTO Status Report
September 12, 2025
Prime Drink Group Terminates Rights Offering and Announces Private Placement
September 4, 2025
Prime Drink Group Provides Bi-Weekly MCTO Status Report and Announces Closing of Private Placement
August 14, 2025
Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 7, 2025
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
August 1, 2025
Prime Medicine Announces Proposed Public Offering of Common Stock
July 30, 2025
Prime Medicine Announces Pricing of Public Offering
July 29, 2025
Prime Drink Group Extends Expiry Date of Its Rights Offering and Announces Delay in Filing Annual Financial Statements
July 29, 2025
Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis
July 16, 2025
Prime Drink Group Announces Change of Auditor
July 3, 2025
Prime Drink Group Announces Launch of Rights Offering
June 18, 2025
Prime Drink Group Provides an Update on Its Bottling Subsidiary Receivership
June 9, 2025
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition
May 19, 2025
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease
May 19, 2025